V114-A + V114-B + Prevnar 13®
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumococcal Infections
Conditions
Pneumococcal Infections
Trial Timeline
Oct 8, 2015 → Jan 20, 2016
NCT ID
NCT02547649About V114-A + V114-B + Prevnar 13®
V114-A + V114-B + Prevnar 13® is a phase 2 stage product being developed by Merck for Pneumococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT02547649. Target conditions include Pneumococcal Infections.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02547649 | Phase 2 | Completed |
Competing Products
20 competing products in Pneumococcal Infections